Evidence map›Paper›PMID 39136017›Full record

ArticleFrontiers in immunology2024

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.

Takahiro Tsujikawa, Kazuchika Ohno, Kei-Ichi Morita, Sumiyo Saburi, Junichi Mitsuda, Kanako Yoshimura, Alisa Kimura, Hiroki Morimoto, Hiroshi Ogi, Saya Shibata and 36 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Takahiro Tsujikawa *Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kazuchika Ohno *Department of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Kei-Ichi Morita *Department of Maxillofacial Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Sumiyo SaburiDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Junichi MitsudaDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kanako YoshimuraDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Alisa KimuraDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroki MorimotoDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hiroshi OgiDepartment of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Saya ShibataSCREEN Holdings, Kyoto, Japan.
Takumi AkashiDepartment of Diagnostic Pathology, Tokyo Medical and Dental University, Tokyo, Japan.
Morito KurataDepartment of Comprehensive Pathology, Tokyo Medical and Dental University, Tokyo, Japan.
Issei ImotoAichi Cancer Center Research Institute, Nagoya, Japan.
Yasushi ShimizuDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Satoshi KanoDepartment of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Akihito WatanabeDepartment of Otolaryngology- Head and Neck Surgery, Keiyukai Sapporo Hospital, Sapporo, Japan.
Tomoko YamazakiDepartment Head and Neck Oncology Division, Saitama Medical University International Medical Center, Hidaka, Japan.
Yukinori AsadaDepartment of Head and Neck Surgery, Miyagi Cancer Center, Natori, Japan.
Ryuichi HayashiDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
Yuki SaitoDepartment of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Hiroyuki OzawaDepartment of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Nobuhiko OridateDepartment of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
Daisuke SanoDepartment of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
Arata HoriiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Yushi UekiDepartment of Otolaryngology Head and Neck Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Takashi MaruoDepartment of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nobuaki MukoyamaDepartment of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Takahito FukusumiDepartment of Otorhinolaryngology-Head and Neck Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroshi IwaiDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital, Osaka, Japan.
Takuo FujisawaDepartment of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital, Osaka, Japan.
Takashi FujiiDepartment of Head and Neck Surgery, Osaka International Cancer Institute, Osaka, Japan.
Ken-Ichi NibuDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Shigemichi IwaeDepartment of Head and Neck Surgery, Hyogo Cancer Center, Akashi, Japan.
Tsutomu UedaDepartment of Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Nobuyuki ChikuieDepartment of Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital, Hiroshima, Japan.
Ryuji YasumatsuDepartment of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Kindai University, Osaka, Japan.
Mioko MatsuoDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hirohito UmenoDepartment of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.
Takeharu OnoDepartment of Otolaryngology-Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.
Muneyuki MasudaDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Satoshi TohDepartment of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kyoko ItohDepartment of Pathology and Applied Neurobiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Shigeru HiranoDepartment of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takahiro AsakageDepartment of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In view of improving biomarkers predicting the efficacy of immunotherapy for head and neck squamous cell carcinoma (R/M HNSCC), this multicenter retrospective study aimed to identify clinical, tumor microenvironmental, and genomic factors that are related to therapeutic response to the anti- Programmed cell death protein 1 (PD-1) antibody, nivolumab, in patients with R/M HNSCC. Methods: The study compared 53 responders and 47 non-responders, analyzing formalin-fixed paraffin-embedded samples using 14-marker multiplex immunohistochemistry and targeted gene sequencing. Results: Of 100 patients included, responders had significantly lower smoking and alcohol index, higher incidence of immune related adverse events, and higher PD-1 ligand (PD-L1) expression in immune cells as well as PD-L1 combined positive score (CPS) than non-responders. The frequency of natural killer cells was associated with nivolumab response in patients with prior cetuximab use, but not in cetuximab-naïve status. Age-stratified analysis showed nivolumab response was linked to high CPS and lymphoid-inflamed profiles in patients aged ≥ 65. In contrast, lower NLR in peripheral blood counts was associated with response in patients aged < 65. Notably, Conclusion: Nivolumab treatment efficacy in HNSCC is influenced by a combination of clinical factors, age, prior treatment, immune environmental characteristics, and gene mutation profiles.

Indexed as

Antineoplastic Agents, ImmunologicalHead and Neck NeoplasmsImmune Checkpoint InhibitorsNivolumabSquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentAdultAgedAged, 80 and overB7-H1 AntigenBiomarkers, TumorFemaleGenomicsHumansMaleMiddle AgedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsNivolumabbiomarkerhead and neck squamous cell carcinomaimmune profilemutationnivolumab

Identifiers

PMID39136017
PMCPMC11317249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.